scholarly journals New Design of a Percutaneous Port System for Continuous Intraperitoneal Insulin Infusion

2019 ◽  
Vol 13 (6) ◽  
pp. 1158-1160
Author(s):  
Cosima Rieger ◽  
Klaus Kurz ◽  
Wiebke Mueller-Hoffmann ◽  
Bernhard Gehr ◽  
Andreas Liebl
Keyword(s):  
Insulin Therapy ◽  
Intensive Insulin Therapy ◽  
Insulin Infusion ◽  
Insulin Pump ◽  
Insulin Delivery ◽  
Insulin Dependent Diabetes Mellitus ◽  
Glucose Measurement ◽  
Dependent Diabetes Mellitus ◽  
Port System ◽  
Intraperitoneal Insulin

Insulin-dependent diabetes mellitus is treated with intensive insulin therapy using multiple daily injections or continuous subcutaneous insulin infusion with insulin pumps. For people with diabetes who cannot achieve acceptable glycemic control despite the use of intensive insulin therapy and continuous glucose measurement, there exists the possibility of continuous intraperitoneal insulin delivery via an implantable pump or a percutaneous port system that is connected to an external insulin pump. In this article, the current second generation of the Accu-Chek® DiaPort system for continuous intraperitoneal insulin delivery with its improvements over the former generation is presented and discussed.

Reassessment of External Insulin Infusion Pumps

1992 ◽  
Vol 8 (6) ◽  
pp. 252-258
Author(s):  
S. Steven Hotta ◽  
Diane Adams
Keyword(s):  
Insulin Therapy ◽  
Intensive Insulin Therapy ◽  
Insulin Infusion ◽  
Insulin Dependent Diabetes Mellitus ◽  
National Institutes Of Health ◽  
Dependent Diabetes Mellitus ◽  
Data Synthesis ◽  
Insulin Dependent ◽  
Patient Use

Objective: To discuss the potential role of continuous subcutaneous insulin infusion (CSII) therapy in patients with insulin-dependent diabetes mellitus (IDDM). Data Sources: Published studies describing intensive insulin therapy are reviewed and evaluated. Data Synthesis: CSII delivers insulin at a preset basal rate and at bolus doses, when needed, throughout the day. Although this technology allows for greater lifestyle flexibility, the risks of hypoglycemia and ketoacidosis are also increased if the pump malfunctions. Studies have shown that CSII therapy may offer some advantages over conventional insulin therapy; however, the full impact of these benefits has yet to be determined. The National Institutes of Health has recommended seven commercially available insulin pumps for patient use. Cost ranges between $2000 and $3500; the average lifespan is about five years. Conclusions: CSII may be a viable alternative to multiple daily injections for maintaining glycemic control in patients with IDDM who require intensive insulin therapy.

Multicentre Trial of a Programmable Implantable Insulin Pump in Type I Diabetes

1995 ◽  
Vol 18 (6) ◽  
pp. 322-325 ◽  
Author(s):  
◽  
M. Pinget ◽  
N. Jeandidier ◽  
F. Ortega ◽  
D. Wix ◽  
...  
Keyword(s):  
Insulin Therapy ◽  
Insulin Infusion ◽  
Multicentre Trial ◽  
Insulin Pump ◽  
Type I Diabetes ◽  
Diabetic Patients ◽  
Type I ◽  
Catheter Obstruction ◽  
Potential Alternative ◽  
Intraperitoneal Insulin

Programmable implantable pumps permitting variable-rate intraperitoneal insulin infusion are currently investigated as a potential alternative to subcutaneous insulin therapy. An improved version of the Siemens implantable system has been evaluated in 6 European centres on 31 type I diabetic patients treated for 10–30 months. Contrary to other pump models there were no proven pump malfunctions and only one no-flow reduction unrelated to catheter obstruction. The latter resulted in 12 surgical catheter replacements. There were 2.0 incidents of programmer malfunctions per patient-year easily managed by reconfiguration or replacement. Insulin remained clear and active in the pump reservoir and glycaemic control remained in the near-normoglycaemic range. Thus, insulin therapy with the Siemens implantable pump is feasible and effective up to 2.5 years.

Sign in / Sign up

Export Citation Format

Share Document